OncoSil Medical (ASX:OSL): Product Launch
OncoSil flagged catalyst-heavy H2 2026 with three critical milestones: US FDA Humanitarian Device Exemption application decision, TRIPP-FFX clinical trial readout (OncoSil + FOLFIRINOX), and Macquarie Park manufacturing facility launch with Cyclotek. Company explicitly signaled this is 'one of the most important periods in Company's development.'
Source: Stocks Down Under
The leadership read
Regulatory Affairs VP for US FDA/HDE pathway management; Commercial/Business Development lead for post-approval market entry (30+ countries already); Manufacturing Operations lead for Cyclotek partnership scaling; Medical Affairs lead for clinical trial adoption strategy.
Market context: the MitchelLake Talent Market Index reads 108.5 — Hot (+10.8 vs prior month); Oceania signal share is rising (+13.1pts).